GlassScriptPhysician profile
Kathleen Linehan
NPI 1184021461
$5,627.02
in general payments reported to CMS, 2019-2025
23 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $1,261 · 2023: $723 · 2024: $1,502 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,823 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.49 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.74 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $666.07 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $657.03 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $611.93 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Axsome Therapeutics, INC. | $411.45 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $346.65 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $312.67 | 2021-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $254.28 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $227.02 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $207.27 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $170.00 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $142.64 | 2021-2025 | Rexulti |
| Corium, LLC | $120.70 | 2021-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $117.86 | 2022 | |
| Sunovion Pharmaceuticals INC. | $90.04 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $66.46 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $56.58 | 2024-2025 | Quviviq, Quviviq |
| Jazz Pharmaceuticals INC. | $44.00 | 2021-2022 | |
| Noven Therapeutics, LLC | $30.45 | 2021-2024 | Xelstrym |
| Eisai INC. | $27.52 | 2021 | |
| Acadia Pharmaceuticals INC | $14.49 | 2025 | Nuplazid |
| Bausch Health US, LLC | $14.16 | 2022 | |
| Almatica Pharma LLC | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Linehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.